Emerging Therapies

San Francisco, CA—Treatment with the novel agent MK-6482 led to promising results in a phase 1/2 clinical trial of patients with metastatic clear-cell renal-cell carcinoma (RCC). Read More ›

Chicago, IL—Tumor-specific antigens provide personalized targets for immunotherapy. Neoantigen vaccines are a new type of immunotherapy that can elicit immune response and achieve remission. Evidence is compelling to support neoantigens as the target of effective immune responses against cancer and to support an association between neoantigen load with improved clinical outcome, said Patrick Alexander Ott, MD, PhD, Clinical Director, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, at ASCO 2019.

Read More ›

High-grade gliomas harboring the histone 3 (H3) K27M mutation are lethal brain tumors associated with a poor prognosis. Read More ›

Treatment options are few for patients with cholangiocarcinoma whose disease progresses while receiving first-line treatment with gemci­tabine (Gemzar) and cisplatin (Platinol), with no established second-line regimen. Read More ›

“Tumor reductions and durable responses were observed in most patients, especially those whose cancers progressed with chemotherapy and multikinase inhibitors,” said Vivek Subbiah, MD, at the 2018 AACR meeting. Read More ›

A novel approach using the investigational toll-like receptor 9 (TLR9) agonist CMP-001 in combination with pembrolizumab (Keytruda) may have the potential to reverse resistance to anti–PD-1 therapy, according to data from a preliminary phase 1b clinical trial. Read More ›

Chicago, IL—Larotrectinib (LOXO-101), an investigational agent that targets tropomyosin receptor kinase (TRK) fusions, has demonstrated excellent, consistent, and durable antitumor activity in a range of tumor types in adults and children, reported lead investigator David M. Hyman, MD, Chief, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, New York City, at the 2017 ASCO annual meeting. Read More ›